RHYTHM PHARMACEUTICALS, INC. (RYTM)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 25M 50M 75M Q3 '21: 1M Q4 '21: 1.8M Q1 '22: 1.5M Q2 '22: 9.1M Q3 '22: 4.3M Q4 '22: 8.8M Q1 '23: 11.5M Q2 '23: 19.2M Q3 '23: 22.5M Q4 '23: 24.2M Q1 '24: 26M Q2 '24: 29.1M Q3 '24: 33.3M Q4 '24: 41.8M Q1 '25: 32.7M Q2 '25: 48.5M Q3 '25: 51.3M Q4 '25: 57.3M Q1 '26: 60.1M Q2 '26: 71.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

0 25M 50M 75M Q3 '21: 806K Q4 '21: 1.6M Q1 '22: 1.3M Q2 '22: 8.7M Q3 '22: 3.8M Q4 '22: 7.8M Q1 '23: 10M Q2 '23: 17M Q3 '23: 20.1M Q4 '23: 21M Q1 '24: 23.2M Q2 '24: 26.1M Q3 '24: 29.4M Q4 '24: 38M Q1 '25: 29.1M Q2 '25: 43M Q3 '25: 45.8M Q4 '25: 52.5M Q1 '26: 53M Q2 '26: 62.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-150M -100M -50M 0 50M 100M 150M Q3 '21: -44.2M Q4 '21: -51M Q1 '22: -52.7M Q2 '22: -45.1M Q3 '22: -39.3M Q4 '22: -42.1M Q1 '23: -52.5M Q2 '23: -46.6M Q3 '23: -44M Q4 '23: -41.3M Q1 '24: -139.9M Q2 '24: -40.5M Q3 '24: -43.9M Q4 '24: -41.3M Q1 '25: -47M Q2 '25: -45.3M Q3 '25: -52.7M Q4 '25: -47.1M Q1 '26: -52.4M Q2 '26: -48.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-150M -100M -50M 0 50M 100M 150M Q3 '21: -35.1M Q4 '21: -42.9M Q1 '22: -52.8M Q2 '22: -45M Q3 '22: -40.9M Q4 '22: -42.5M Q1 '23: -52.2M Q2 '23: -46.7M Q3 '23: -44.2M Q4 '23: -41.6M Q1 '24: -141.4M Q2 '24: -32.3M Q3 '24: -43.6M Q4 '24: -43.3M Q1 '25: -49.5M Q2 '25: -46.6M Q3 '25: -52.9M Q4 '25: -47.5M Q1 '26: -55.6M Q2 '26: -49.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 3.5M 7M 10.5M Q3 '21: 222K Q4 '21: 236K Q1 '22: 230K Q2 '22: 378K Q3 '22: 497K Q4 '22: 1M Q1 '23: 1.4M Q2 '23: 2.2M Q3 '23: 2.4M Q4 '23: 3.2M Q1 '24: 2.8M Q2 '24: 2.9M Q3 '24: 3.8M Q4 '24: 3.8M Q1 '25: 3.6M Q2 '25: 5.5M Q3 '25: 5.5M Q4 '25: 4.8M Q1 '26: 7.2M Q2 '26: 8.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-60M -40M -20M 0 20M 40M 60M Q3 '21: -40.2M Q4 '21: -40.5M Q1 '22: -53.6M Q2 '22: -38.8M Q3 '22: -47M Q4 '22: -34M Q1 '23: -36.4M Q2 '23: -41.1M Q3 '23: -29.3M Q4 '23: -29.4M Q1 '24: -40.7M Q2 '24: -29.1M Q3 '24: -25.2M Q4 '24: -18.8M Q1 '25: -40.4M Q2 '25: -23.3M Q3 '25: -26.6M Q4 '25: -25.4M Q1 '26: -44.2M Q2 '26: -9.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-60M -40M -20M 0 20M 40M 60M Q4 '17: -7.9M Q3 '18: -17.3M Q4 '18: -21.4M Q1 '19: -32.2M Q2 '19: -27.9M Q3 '19: -33.9M Q4 '19: -32.2M Q4 '20: -29.2M Q1 '21: -33.5M Q2 '21: -32.1M Q3 '21: -40.3M Q4 '21: -40.5M Q1 '22: -53.8M Q2 '22: -38.9M Q3 '22: -47.1M Q4 '22: -34M Q1 '23: -36.5M Q2 '23: -41.1M Q3 '23: -29.3M Q4 '23: -29.4M Q3 '18 Q2 '19 Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 25M 50M 75M Q1 '20: 44M Q2 '20: 44.1M Q1 '21: 48.5M Q2 '21: 50.2M Q3 '21: 50.2M Q1 '22: 50.3M Q2 '22: 50.4M Q3 '22: 51.4M Q1 '23: 56.7M Q2 '23: 56.9M Q3 '23: 57.9M Q1 '24: 60.1M Q2 '24: 61M Q3 '24: 61.2M Q1 '25: 63.1M Q2 '25: 63.7M Q3 '25: 66.3M Q1 '26: 68M Q2 '26: 68.6M Q1 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6.00 -4.00 -2.00 0.00 2.00 4.00 6.00 Q3 '21: -1.29 Q4 '21: -1.36 Q1 '22: -3.31 Q2 '22: -3.50 Q3 '22: -3.59 Q4 '22: -3.47 Q1 '23: -3.34 Q2 '23: -3.27 Q3 '23: -3.24 Q4 '23: -3.20 Q1 '24: -4.63 Q2 '24: -4.36 Q3 '24: -4.33 Q4 '24: -4.35 Q1 '25: -2.81 Q2 '25: -3.01 Q3 '25: -3.10 Q4 '25: -3.11 Q1 '26: -3.13 Q2 '26: -3.11 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.